Member Info for johnlaycock

I'm a very LTH and even I am a bit concerned about the lack of news and any updates from the new CEX. I am though comforted by the recent Chair share purchase and the hiring of new staff. I don't doubt lots is happening in the background but it would be good for some progress news soon.

Surely Roger holds no more shares if he thinks it will get back to 1.5p by the end of the week?

Thanks Porsh for the info, sounds promising. Here's hoping we may have some good news on various fronts soon.

Speaking of Scotland, remember this is being published on 30th September:

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

The award nomination is for past work not a future contract!!

Exactly John, she has not been brought in as Head of BD as your post indicated.

John...where do you see the new hire is head of business development?

I am a bit sceptical that this has suddenly been raised as a barrier for sales. As others have astutely indicated, the NHS were instrumental in the design of the tests so you can only assume they would have considered the IT implications?

Also some trusts (Manchester , Brighton) are already successfully using the tests so if they can do it, why can't others???

One for the birds that assumption Joey.

Why did the Chair recently spend 30k of his own money if he didn't think medium/ long term his investment would blossom?

Well it went from sub 1.5p to 5p quite quickly recently, so no reason with some expected good news, this won't happen again!

...but Wes Streeting announced that there was going to be a big shift from treating sickness to preventing it. You would have thought Genomic testing would be a ingredient of this ?

The Darzi report specifically mentions genomic testing but describes turnaround times as being poor. Enter POC tests then!

Yes after a few days so totally irrelevant in terms of sales in this period as per your post.

Yes of course Gino will do better with the NHS than his predecessor now NICE has recommended the stroke test as the preferred PCT.

Plus more money/ investment for new technologies....

Roger, don't forget the companys test can be used in the lab too so assuming they are pursuing this route too, it's win/win.

Roger...the company has never specifically mentioned September in any of their comms in terms of sales. I think this is yet another example of you stirring things up to suit whatever agenda you hold.

Roger - where do you see she is heading up the business development team?

Let's hope next week sees the start of the avalanche of positive RNS's we are waiting for.